FREQUENCY THERAPEUTICS, INC. (FREQ): Price and Financial Metrics
GET POWR RATINGS... FREE!
FREQ Stock Price Chart Interactive Chart >
FREQ Price/Volume Stats
| Current price | $4.02 | 52-week high | $5.66 |
| Prev. close | $4.06 | 52-week low | $1.00 |
| Day low | $4.02 | Volume | 2,549 |
| Day high | $4.02 | Avg. volume | 342,075 |
| 50-day MA | $3.17 | Dividend yield | N/A |
| 200-day MA | $2.11 | Market Cap | 141.75M |
FREQUENCY THERAPEUTICS, INC. (FREQ) Company Bio
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. T
Latest FREQ News From Around the Web
Below are the latest news stories about FREQUENCY THERAPEUTICS INC that investors may wish to consider to help them evaluate FREQ as an investment opportunity.
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis ProgramLEXINGTON, Mass., December 19, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clinical development and translation eff |
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing LossLEXINGTON, Mass., December 15, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Company’s second hearing restoration candidate for sensorineural hearing loss (SNHL). |
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical ResultsLEXINGTON, Mass., November 17, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical r |
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial ResultsLEXINGTON, Mass., November 08, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022. |
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing LossLEXINGTON, Mass., October 12, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of s |
FREQ Price Returns
| 1-mo | 1.77% |
| 3-mo | 67.50% |
| 6-mo | 80.27% |
| 1-year | -28.47% |
| 3-year | -84.91% |
| 5-year | N/A |
| YTD | 4.42% |
| 2022 | -24.95% |
| 2021 | -85.45% |
| 2020 | 101.14% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...